A new myTomorrows survey of physicians in the United States highlights the need for smarter, AI-driven tools to overcome inefficiencies in clinical trial access and improve patient care timelines.
Image Credit: Adobe Stock Images/jam
Navigating the clinical trial landscape has become a major bottleneck in patient care, with 72% of US physicians reporting that time-consuming searches for relevant trials are delaying treatment access. As the number of clinical trials and investigational drugs continues to surge, physicians face growing frustration with outdated, fragmented tools that complicate patient enrollment. According to a new myTomorrows report, the widening gap between medical innovation and clinical trial access underscores an urgent need for smarter, AI-powered solutions to streamline trial matching and referral processes—ultimately accelerating patient access to novel therapies.1
"Navigating the clinical trial landscape is often complex, time-consuming, and frustrating for both patients and physicians," said Michel van Harten, MD, CEO, myTomorrows, in a press release. "That's why it's essential that healthcare professionals and patients have trusted tools that make finding the right clinical trials faster, simpler, and more transparent.”
Other notable findings from the survey, which featured 100 physicians, include:
According to myTomorrows, while clinical trials are essential to bringing new treatments to patients, the growing volume—now exceeding 500,000 globally with more than 8,000 drugs in development—has made it increasingly difficult for physicians to identify and enroll eligible patients. The process remains largely manual and fragmented, creating added burden for healthcare providers and reducing visibility into suitable trial options. As a result, both patient access to cutting-edge therapies and the broader pace of therapeutic development are being slowed.1
“At myTomorrows, we are committed to elevating physicians' voices and creating practical, human-centered solutions that expand access to treatment options,” continued van Harten, in the press release. “Our AI-powered technology streamlines every step of the process, connecting stakeholders in a more equitable clinical trial ecosystem, one that delivers meaningful impact for patients, both today and in the future."
Check out our May interview with van Harten here.
References
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
